

PRODUCT INFORMATION



Tat-CBD3^{A6K} (trifluoroacetate salt)

Item No. 37449

Formal Name: L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-alanyl-L-arginyl-L-seryl-L-arginyl-L-leucyl-L-lysyl-L- α -glutamyl-L-leucyl-L-arginylglycyl-L-valyl-L-prolyl-L-arginylglycyl-L-leucine, trifluoroacetate salt

Peptide Sequence: YGRKKRRRQRRRARSRLKELRGVPRGL-OH

MF: C₁₃₇H₂₅₀N₆₀O₃₂ • XCF₃COOH

FW: 3,249.8

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

H—Tyr—Gly—Arg—Lys—Lys—Arg—Arg—Gln—Arg—Arg—Arg—Ala—Arg—Ser—Arg—Leu—Lys—Glu—Leu—Arg—Gly—Val—Pro—Arg—Gly—Leu—OH
• XCF₃COOH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tat-CBD3^{A6K} (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the Tat-CBD3^{A6K} (trifluoroacetate salt) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Tat-CBD3^{A6K} is a peptide and derivative of the N-type voltage-gated calcium channel Ca_v2.2 and collapsin response mediator protein 2 (CRMP2) protein-protein interaction inhibitor Tat-CBD3 (Item No. 37448).^{1,2} Tat-CBD3^{A6K} (10 mg/kg) prevents decreases in the paw withdrawal threshold in a rat model of antiretroviral neuropathic pain induced by d4T (stavudine; Item No. 14975) and decreases the number of action potentials from dorsal root ganglia (DRG) neurons isolated from the same rats.¹ Dural administration of Tat-CBD3^{A6K} (30 μ M/animal) decreases meningeal blood flow induced by the terpene alkaloid capsaicin (Item Nos. 92350 | 10010743) in rats.²

References

1. Piekarz, A.D., Rue, M.R., Khanna, M., *et al.* CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. *Mol. Pain.* **8**, 54 (2012).
2. Wilson, S.M., Brittain, J.M., Piekarz, A.D., *et al.* Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. *Channels (Austin)* **5**(5), 449-456 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM